Scientists have created the first off-the-shelf CAR-T cells for a deadly form of adult leukemia, scientists in China told the (virtual) annual meeting of the American Association for Cancer Research on Tuesday. If the early results from their small study holds up, it would be an advance not only in this rare cancer but also for the CAR-T industry and potentially other cancers: showing the feasibility of CAR-Ts that could be delivered more quickly and affordably because they don’t have to be genetically engineered from each patient’s own cells.

In their first-in-human trial, physicians gave the off-the-shelf CAR-Ts to five patients with T-cell acute lymphoblastic leukemia (T-ALL), Xinxin Wang of Shanghai-based Gracell Biotechnologies told the online attendees. All five had relapsed after standard cancer treatment. One patient showed no enduring benefit. But four had so few leukemic cells four months after the CAR-T infusion they were barely detectable.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy